Radium Ra-223
- Generic Name
- Radium Ra-223
- Drug Type
- Small Molecule
- Chemical Formula
- Ra
- CAS Number
- 15623-45-7
- Unique Ingredient Identifier
- 8BR2SOL3L1
- Background
Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
- Conditions
- Castration-Resistant Prostatic Cancer
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 363
- Registration Number
- NCT02398526
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT02278055
- Locations
- 🇺🇸
New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- Drug: Placebo (saline)
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 283
- Registration Number
- NCT02258451
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- Drug: Placebo (saline)Other: Background hormonal therapy
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 99
- Registration Number
- NCT02258464
Radium-223 in Combination With Enzalutamide
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 45
- Registration Number
- NCT02225704
- Locations
- 🇮🇪
Mater Private Hospital, Dublin 7, Ireland
🇮🇪Galway University Hospital, Galway, Ireland
🇮🇪St Vincents University Hospital / AMNCH, Dublin, Ireland
Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Bone Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Device: Biomarker analysis
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- Duke University
- Target Recruit Count
- 20
- Registration Number
- NCT02204943
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1474
- Registration Number
- NCT02141438
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: Matching placebo (normal saline)Drug: Prednisone/Prednisolone
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 806
- Registration Number
- NCT02043678
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 68
- Registration Number
- NCT02034552
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 391
- Registration Number
- NCT02023697
- Locations
- 🇧🇷
Instituto do Câncer do Estado de São Paulo, São Paulo, Sao Paulo, Brazil
🇧🇷Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Hospital de ClÃnicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.